$15.22+0.24 (+1.60%)
Jade Biosciences, Inc.
Jade Biosciences, Inc. in the Healthcare sector is trading at $15.22. Wall Street consensus targets $49.00 (7 analysts), implying a +221.9% move over the next 12 months. The stock is currently 46% below its 52-week high of $28.00, remaining 5.9% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Induci...
Jade Biosciences (NASDAQ:JBIO) said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company’s plan to advance the antibody into patient studies for IgA nephropathy. Chief Executive Officer Tom Frohlich said JADE101,
Jade Biosciences stock overview following recent trading performance Jade Biosciences (JBIO) has drawn attention after a recent stretch of trading that left the stock down 3.1% on the day and 11.2% over the past week, sharpening interest in its recent gains over the past 3 months and year. See our latest analysis for Jade Biosciences. Despite the weak recent share price returns, with the stock down 21.2% over 30 days, Jade Biosciences still shows strong momentum over longer periods. This is...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Jade Biosciences (NASDAQ:JBIO) outlined its strategy and near-term milestones at the Oppenheimer Life Sciences Conference, where CEO Tom Frohlich described the company’s focus on developing “best-in-class” monoclonal antibodies for autoimmune diseases using high-affinity binding and half-life extens
Jade Biosciences Inc. (NASDAQ:JBIO) is one of the overlooked growth stocks to buy. On January 7, H.C. Wainwright initiated coverage of Jade Biosciences with a Buy rating and $25 price target. The firm identified the company as being strategically positioned to secure a leadership role within the autoimmune market. The firm projects that JADE101, specifically […]